Pepscan Therapeutics announces establishment of Scientific Advisory Board
Pepscan Therapeutics announced the establishment of a Scientific Advisory Board (SAB). The SAB will guide the company in the further development and application of its core protein mimicking technology for the creation of novel therapeutic peptide drugs and monoclonal antibodies.
The Scientific Advisory Board is chaired by Sir Gregory Winter, a scientific pioneer of protein engineering and therapeutic monoclonal antibodies. He invented techniques to make humanized and fully human antibodies for therapeutic uses. Winter co-founded Cambridge Antibody Technologies, Domantis and Bicycle Therapeutics and is Deputy Director at the Laboratory of Molecular Biology, as well as at the MRC Centre for Protein Engineering, in Cambridge (UK). Other members of the Scientific Advisory Board are:
- Andrew Hamilton, the Vice-Chancellor of the University of Oxford and former Professor of Chemistry at Yale, a leading expert in the field of mimics of protein surface domains;
- Andreas Plückthun, Professor of Biochemistry at the University of Zürich and co-director of the department, a renowned pioneer in the antibody, protein engineering and directed evolution field, and co-founder of Morphosys and Molecular Partners;
- Reinhold Foerster, Professor of immunology at the Medical School in Hannover, and an internationally acknowledged expert on chemokine receptors.
"We are very pleased with the formation of our Scientific Advisory Board and feel honored to collaborate with this experienced team that is highly committed advising the Company on moving forward its research and development program” said Wim Mol, CEO of Pepscan. “The complementary knowledge of the renowned scientists in this team will play a significant role in our R&D programs and success of the company.”
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
